Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease

  • AstraZeneca Plc (NASDAQ:AZNshared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG).
  • Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks.
  • Ultomiris was also well tolerated throughout this analysis.
  • gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.
  • Also Read: Roche And AstraZeneca Settle Ultomiris Patent Lawsuit.
  • Ultomiris demonstrated statistically significant improvements from baseline in functional activity, muscle strength, and quality of life at 60 weeks, including Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score. 
  • Additionally, patients transitioning from placebo (n=83) showed a rapid response at a similar magnitude and time course as those who received Ultomiris during the randomized control period.
  • The most common adverse events (AEs) were headache (16.6%) and diarrhea (13.6%).
  • Regulatory submissions for Ultomiris for the treatment of gMG are currently under review with multiple health authorities, including in the U.S., European Union (EU), and Japan.
  • Price Action: AZN shares are up 2.24% at $68.56 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.